Traitement en cours

Veuillez attendre...

PATENTSCOPE sera indisponible durant quelques heures pour des raisons de maintenance le mardi 27.07.2021 à 12:00 PM CEST
Paramétrages

Paramétrages

Aller à Demande

1. WO2007108621 - UTILISATION D'ARNSI POUR INHIBER L'EXPRESSION DU NF-ϰB/RELA

Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

[ EN ]

[CLAIMS]
[Claim 1]
<iO56> siRNA having one of nucleotide sequences represented as SEQ. ID. Nos. 1 to 30 which bind with mRNA transcribed from a gene coding for NF-κB/RelA to inhibit NF-κB/RelA expression in a cell.
<1057>
[Claim 2]
<iO58> siRNA of claim 1, which further comprises 3' overhang having one or two unpaired nucleotides at 3'-terminal of the nucleotide sequence.
<1059>
[Claim 3]
<i060> siRNA of claim 1, which further comprises 2'-0-methyl or phosphorothioate introduced at each of bases of the nucleotide sequence.
<1061>
[Claim 4]
<iO62> siRNA of claim 1, which has a nucleotide sequence selected from the group consisting of SEQ. ID. Nos. 2, 3, 8, 9, 14, 16, 17, 26, 27, 28 and 30.

<1063>
[Claim 5]
<iO64> siRNA of claim 1, which has a nucleotide sequence of SEQ. ID. No. 17.

<1065>
[Claim 6]
<iO66> A pharmaceutical composition for treating rheumatoid arthritis which comprises an active ingredient of siRNA having one of nucleotide sequences represented as SEQ. ID. Nos. 1 to 30 and pharmaceutically acceptable carrier thereof.
<1067>
[Claim 7]
<iO68> The pharmaceutical composition for treating rheumatoid arthritis of claim 6, which further comprises 3' overhang having one or two unpaired nucleotides at 3'-terminal of the nucleotide sequence.

<1069>
[Claim 8]
<i070> The pharmaceutical composition for treating rheumatoid arthritis of claim 6, which further comprises 2'-0-methyl or phosphorothioate at each of bases of the nucleotide sequence.
<1071>
[Claim 9]
<iO72> A pharmaceutical composition for treating rheumatoid arthritis which comprises an active ingredient of siRNA having a nucleotide sequence represented as SEQ. ID. No. 17 and pharmaceutically acceptable carrier thereof.
<1073>
[Claim 10]
<iO74> A pharmaceutical composition for treating rheumatoid arthritis which comprises an active ingredient of siRNA having one of nucleotide sequences represented as SEQ. ID. Nos. 1 to 30 and a nucleotide sequence represented as SEQ. ID. No. 51, and pharmaceutically acceptable carrier thereof.
<1075>
[Claim 11]
<iO76> A pharmaceutical composition for treating rheumatoid arthritis which comprises an active ingredient of siRNAs having nucleotide sequences represented as SEQ. ID. Nos. 17 and 51, and pharmaceutically acceptable carrier thereof.